Q3 IPO Volume On The Up
Q3 saw a rise in the volume of initial public offerings, sparking hopes for a potential IPO rebound in 2016.
You may also be interested in...
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.